Innovative funding partner throughout the growth life-cycle

Latest developments

News, Portfolio 28/07/2022              

European Commission approves Kinpeygo® for adults with primary IgA nephropathy

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the European Commission (EC) has granted conditional marketing authorization for Kinpeygo® for the treatment of primary immunoglobulin A…
News, Portfolio 25/07/2022              

Sequana Medical secures EUR 10 million loan facility with Kreos Capital.

Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces it has entered into a…
News, Portfolio 22/07/2022              

Beckman Coulter and Scopio Labs Partner to Accelerate Adoption of Hematology Digital Cell Morphology Platform

Beckman Coulter, a global leader in clinical diagnostics, and Scopio Labs, a medtech company that develops AI-powered workflow solutions, announced today a worldwide partnership to accelerate adoption of Scopio's next generation…

Subscribe to our mailing list

Get our newsletter, Kreos updates and information on our events right to your mailbox.

Market Leading Growth Debt Investor for +22 years

Kreos Capital provides innovative and flexible debt solutions to equity-backed, pan-European and Israeli high-growth companies in the technology and healthcare sectors.

For over 22 years, our sole focus has been to support our ambitious ecosystem with personal, adaptable and responsive financing through every stage of the growth life cycle – from entry level through to late-stage growth including pre and post-IPO.